S moment t 5t ETASLlu,n Dr the Des suits

o

D Talk to your healthcare provider ~

Learn about MS medications that

are approved to slow the progress

of your disease from the first event

D Call 1-800-788-1467 or visit

www.mspathways.com today to find

out more and get personalized

support by your B.E.T.A. nurse

At the first sign of MultiDle Sclerosis ucan do somethin

control" e's t to los"".

Ha~'er IleahhCar'~ <':!2007 Boyer HeallhCa::-e P'lIDr",aceU~ICal$ln~" Wayne, NJ O?lI4<l AI'i rights ,",",,'ed, 'o'alll.factUreu .b, Ch Imp Cor>oMlon, £rnef}'lille. CA 9'4,08hannaoel.lllc.ab; [;iUril:uloJJ by Bayer HealthCat1l fl"armac~utical, inc -- ..._.. ....... n~._..l ;_..IUi' ,.....:.. d ',Ion?

DO SOMETHING

II is i b Sclerosis at th

You may have had one or more of these symptoms:

Vision problems

Numbness or tingling

Trouble maintaining balance

Lapses in memory

Fatigue or weakness

Loss of coordination

The NatiDnal Multiple Sclerosis Society (NMSS) encourages patients to begin MS therapy as early as possible.

You may not be feeling or experiencing any

noticeable symptoms. But MS can cause

your immune system to attack the nerves

of your brain and spinal cord. The harm

may be "silent" as it takes place in your

nervous system yet it can cause serious

problems later if left untreated. In fact, a

study has suggested that MS can cause 4 times the damage during the first year than later on.

Consult your doctor immediately if you have any symptoms that might mean you have MS.

e 11o ... I..,.S to SiD isease activity

"The earlier 5% of people ve h you treat with first event wil evelOD MS" an effective within 2 years if left untreated

therapy, the A new study, called the BENEFITbetter the study, showed that treatment wioutcome."

ETASERON at the first event mayDr. Ludwig Kappas,

lower the risk of szettiprincipal investigator of the BENEFIT study Iinica lIy di

Y 50%

• In this 2-year study, patients who

went on BETASERON at the first

event slowed the progress ei~r MS to clinically diagnosed MS

by 1 year compared with those

on placebo

'By MRI criteria.

The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Injection-site necrosis has been reported in 5% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. _

.. . :J 8ET~SERON· Please see Medication GUide enclosed. J lTtJTtP!'EJlON E£mlbl ...

u

BETASERON j,s the on and only high-dose, high-frequency inteneron beta FIDA-approved for treatment at the first

Sevent

3

of all patients completing the BENEFIT to rominue with BETAsrru

SERO arKS

study had the folio See tor rself Inaients treated wit TASA'

results·

Patients on BETASERON with a first MS event experienced a "The [BENEFIT] study TASERON was

cea risk of developing clinically OIagnose results should help ccepted . _ _ _ _ ears compared with placebo. This means that patients on doctors and patients

of patients who com pleted theBETASERON were more likely to be free of MS episodes over 2 years in their discussions

BENEFIT study. This level oftha n the untreated grou p. about starting acceptance was comparable to

treatment as early the placebo group as possible."

Based on the results of the recent Dr. Chris Polman, Professor of Neurology, BENEFIT study, BETASER~JrJls VU Medical Center, en effectille treatme Amsterdam, The Netherlands

for patients at the first MS event

study ,;ho~e

as part of a 3-year follow-up study

Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms.

. . :J 8ETI=ISERONPlease see Medication GUide enclosed. ..::J (IImJ1FEROlJ BLmlh.'.

NOT

DO SOMETHING

T, SERDN and LI 'G IlII:iIlts th BETASE're out y people 5t

• The Long-term Follow-up (lTF) study followed patients who used

BETASERON for 17 years

his study showed that BETASERON is

a treatment that people with MS can slav on for the long term

by physicians and ,patients

The most commonly reported adverse reactions are lymphopenia. injection-site reaction, asthenia, flu-like symptom complex, headache, and pain.

Please see Medication Guide enclosed.

BETASERON has been studied and trusted for

r compared with placebo

:;J BETr:tISERONJ 1r-lTEArEAON efT~lIll -

Patients on long-term treatment with

BETASERON stayed healthier longer,

slowing the progress of their MS bv more than 6 years

Over 17 years, the LTF study found that

long-term use of BETASERON is S

ective, and well tolerat

Patients who had been on BETASERON for

17 years experienced a delay in the progress

of their MS, giving them nearly 60% more u-ane-free" years from diagnosis compared

with other treatments

Patients on BETASERON with a first MS event

s s best SUitS." "

SUitS

from the fi rst to the

second event

of patients who com pleted

the BENEFIT study. This level of

acceptance was comparabl.e to the

placebo group

s r the best snnnnrt

s rat

That's where you'll find B.E.T.At nurses, who are

specialists in MS. "They'll give lloU supp y time day Dr night to help you start and

stay on BETASERON.

s, com or callEnro II h ....f ~u

1-80··- for the support you need to stay on track.

'In an independent study, MS PathwaysSM was rated significantly higher on how valuable it IS to people liVing with MS compared with other support programs.

18etaseron Education, Training, & Assistance.

MS Path"

S PathwaySSM prD best by people with MS.

BETASERON (interferon beta-lb) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of cl'inical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

The most commonly reported adverse reactions are lymphopenia, Injection-site reaction, asthenia, flu-like symptom complex, headache, and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 5% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely.

Please see Medication Guide enclosed.

BETASERON is a registered trademark and MS Pathways and B.E.T.A. are service marks of Bayer HealthCare Pharmaceuticals Inc.

:) 8ETI=ISERON":J I1NHJlt'EAUN eruH

• nE e

at y eo to k W:

ho have had a fi rst e ill within 2 years if left untreated

•

Patients on BETASERON with a first MS event experienced a

o~ reduced risk of developing clinicalty S over 2 years compared with placebo

is a safe and effective treatment tor S as shown in more than 17 years of study

• People on BETASERON for 17 years had nearly 60% more ucane-rree" vears t

There is more to learn about the BENEFIT and long-term Follow-up (lTF) studies in the enclosed booklet

•By MRI criteria.

t Versus patients on other disease-modifying therapies or no treatment.o